tradingkey.logo

Align Technology Q4 revenue beats estimates

ReutersFeb 4, 2026 9:21 PM


Overview

  • Medical device firm's Q4 revenue grew 5.3% yr/yr, beating analyst expectations

  • Adjusted EPS for Q4 beat analyst expectations

  • Company repurchased 0.7 mln shares, completing $200 mln buyback plan


Outlook

  • Align expects Q1'26 worldwide revenue between $1,010M and $1,030M, up 3% to 5% year-over-year

  • Align expects 2026 worldwide revenue growth of 3% to 4% year-over-year

  • Align expects 2026 Clear Aligner volume growth to be up mid-single digits year-over-year


Result Drivers

  • CLEAR ALIGNER VOLUME - Q4 volume reached a record 676.9 thousand cases, driven by growth in EMEA, Latin America, and Asia Pacific, with stability in North America

  • SYSTEMS AND SERVICES GROWTH - Q4 revenues increased 10.3% sequentially, driven by iTero Lumina scanner sales

  • FOREIGN EXCHANGE IMPACT - Q4 revenues were unfavorably impacted by foreign exchange sequentially but favorably year-over-year


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$1.05 bln

$1.03 bln (12 Analysts)

Q4 Adjusted EPS

Beat

$3.29

$2.97 (14 Analysts)

Q4 EPS

$1.89

Q4 Adjusted Net Income

Beat

$236 mln

$214.59 mln (11 Analysts)

Q4 Net Income

$135.80 mln

Q4 Gross Profit

$683.60 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Align Technology Inc is $180.50, about 14.9% above its February 3 closing price of $157.05

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nBw4s7XQya

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI